You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

216 Results
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Curative
Dec 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Dec 2025
Guidelines and Advice
Status: Current
ID: GL1-10
Version: 4
Mar 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Rectal
Intent: Neoadjuvant
Jan 2026
Drug
Other Name(s): Poteligeo®
May 2024
Regimen
Cancer Type:
Central Nervous System
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Mar 2026
Drug
Other Name(s): Zolinza®
Updated
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
New
Apr 2026
Drug
Other Name(s): Voranigo™
Updated
Apr 2026
Guidelines and Advice

Pages